Why the study?
Does a drug-coated balloon-only strategy improve outcomes compared to drug-eluting stents, plain-old balloon angioplasty, or bare metal stents in patients with de novo coronary artery disease?
Does a drug-coated balloon-only strategy improve outcomes compared to drug-eluting stents, plain-old balloon angioplasty, or bare metal stents in patients with de novo coronary artery disease?
A drug-coated balloon-only strategy appears comparable to drug-eluting stents and superior to plain balloon angioplasty or bare metal stents for selected de novo coronary lesions, though further evidence is needed before widespread use.
Supports DCB-only for selected de novo lesions; extends evidence for non-stent PCI options.
Interventions with a DCB-only strategy are comparable to those of drug-eluting stents and superior to plain-old balloon angioplasty or bare metal stents for the treatment of selected de novo coronary lesions. Additional evidence is still warranted to confirm the value of DCB before widespread clinical utilization can be recommended.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2023) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: